Risk factors, management, and outcomes of amniotic fluid embolism: A multicountry, population-based cohort and nested case-control study

English version

Autoři: Kathryn E. Fitzpatrick ^aff001; Thomas van den Akker ^aff002; Kitty W. M. Bloemenkamp ^aff003; Catherine Deneux-Tharaux ^aff004; Alexandra Kristufkova ^aff005; Zhuoyang Li ^aff006; Timme P. Schaap ^aff003; Elizabeth A. Sullivan ^aff006; Derek Tuffnell ^aff008; Marian Knight ^aff001
Působiště autorů: National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom ^aff001; Department of Obstetrics and Gynaecology, Leiden University Medical Centre, Leiden, the Netherlands ^aff002; Birth Centre Wilhelmina Children Hospital, Division of Woman and Baby, University Medical Center Utrecht, Utrecht, the Netherlands ^aff003; Université de Paris, CRESS, Obstetrical Perinatal and Pediatric Epidemiology Research Team, EPOPé, INSERM, Paris, France ^aff004; First Department of Obstetrics and Gynaecology, Faculty of Medicine, Comenius University, Bratislava, Slovakia ^aff005; Australian Centre for Public and Population Health Research, Faculty of Health, University of Technology Sydney, Sydney, Australia ^aff006; Faculty of Health and Medicine, University of Newcastle, Callaghan, Australia ^aff007; Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom ^aff008
Vyšlo v časopise: Risk factors, management, and outcomes of amniotic fluid embolism: A multicountry, population-based cohort and nested case-control study. PLoS Med 16(11): e32767. doi:10.1371/journal.pmed.1002962
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pmed.1002962

Souhrn

Background

Amniotic fluid embolism (AFE) remains one of the principal reported causes of direct maternal mortality in high-income countries. However, obtaining robust information about the condition is challenging because of its rarity and its difficulty to diagnose. This study aimed to pool data from multiple countries in order to describe risk factors, management, and outcomes of AFE and to explore the impact on the findings of considering United Kingdom, international, and United States AFE case definitions.

Methods and findings

A population-based cohort and nested case-control study was conducted using the International Network of Obstetric Survey Systems (INOSS). Secondary data on women with AFE (n = 99–218, depending on case definition) collected prospectively in population-based studies conducted in Australia, France, the Netherlands, Slovakia, and the UK were pooled along with secondary data on a sample of control women (n = 4,938) collected in Australia and the UK. Risk factors for AFE were investigated by comparing the women with AFE in Australia and the UK with the control women identified in these countries using logistic regression. Factors associated with poor maternal outcomes (fatality and composite of fatality or permanent neurological injury) amongst women with AFE from each of the countries were investigated using logistic regression or Wilcoxon rank–sum test. The estimated incidence of AFE ranged from 0.8–1.8 per 100,000 maternities, and the proportion of women with AFE who died or had permanent neurological injury ranged from 30%–41%, depending on the case definition. However, applying different case definitions did not materially alter findings regarding risk factors for AFE and factors associated with poor maternal outcomes amongst women with AFE. Using the most liberal case definition (UK) and adjusting for the severity of presentation when appropriate, women who died were more likely than those who survived to present with cardiac arrest (89% versus 40%, adjusted odds ratio [aOR] 10.58, 95% confidence interval [CI] 3.93–28.48, p < 0.001) and less likely to have a source of concentrated fibrinogen (40% versus 56%, aOR 0.44, 95% CI 0.21–0.92, p = 0.029) or platelets given (24% versus 49%, aOR 0.23, 95% CI 0.10–0.52, p < 0.001). They also had a lower dose of tranexamic acid (median dose 0.7 g versus 2 g, p = 0.035) and were less likely to have had an obstetrician and/or anaesthetist present at the time of the AFE (61% versus 75%, aOR 0.38, 95% CI 0.16–0.90, p = 0.027). Limitations of the study include limited statistical power to examine factors associated with poor maternal outcome and the potential for residual confounding or confounding by indication.

Conclusions

The findings of our study suggest that when an AFE is suspected, initial supportive obstetric care is important, but having an obstetrician and/or anaesthetist present at the time of the AFE event and use of interventions to correct coagulopathy, including the administration of an adequate dose of tranexamic acid, may be important to improve maternal outcome. Future research should focus on early detection of the coagulation deficiencies seen in AFE alongside the role of tranexamic acid and other coagulopathy management strategies.

Klíčová slova:

Amniotic fluid – Australia – Birth – Cardiac arrest – Fibrinogen – Obstetrics and gynecology – Platelets – Coagulopathy

Zdroje

1. Fitzpatrick KE, Tuffnell D, Kurinczuk JJ, Knight M. Incidence, risk factors, management and outcomes of amniotic-fluid embolism: a population-based cohort and nested case-control study. BJOG. 2016;123(1):100–9. Epub 2015 Feb 12. doi: 10.1111/1471-0528.13300 25683758.

2. Conde-Agudelo A, Romero R. Amniotic fluid embolism: an evidence-based review. Am J Obstet Gynecol. 2009;201(5):445 e1–13. doi: 10.1016/j.ajog.2009.04.052 19879393.

3. Knight M, Nair M, Tuffnell D, Shakespeare J, Kenyon S, Kurinczuk JJ, et al. Saving Lives, Improving Mothers' Care—Lessons learned to inform maternity care from the UK and Ireland Confidential Enquires into Maternal Deaths and Morbidity 2013–15. Oxford: National Perinatal Epidemiology Unit, University of Oxford; 2017.

4. Australian Institute of Health and Welfare. Maternal deaths in Australia 2012–2014. PER 92. Canberra: AIHW; 017.

5. Bonnet MP, Zlotnik D, Saucedo M, Chassard D, Bouvier-Colle MH, Deneux-Tharaux C, et al. Maternal Death Due to Amniotic Fluid Embolism: A National Study in France. Anesth Analg. 2018;126(1):175–82. doi: 10.1213/ANE.0000000000002511 28961562.

6. Knight M, Tuffnell D, Brocklehurst P, Spark P, Kurinczuk JJ, System UKOS. Incidence and risk factors for amniotic-fluid embolism. Obstet Gynecol. 2010;115(5):910–7. doi: 10.1097/AOG.0b013e3181d9f629 20410762.

7. Schaap T, Bloemenkamp K, Deneux-Tharaux C, Knight M, Langhoff-Roos J, Sullivan E, et al. Defining definitions: a Delphi study to develop a core outcome set for conditions of severe maternal morbidity. BJOG. 2019;126(3):394–401. Epub 2017 Aug 24. doi: 10.1111/1471-0528.14833 28755459.

8. Clark SL, Romero R, Dildy GA, Callaghan WM, Smiley RM, Bracey AW, et al. Proposed diagnostic criteria for the case definition of amniotic fluid embolism in research studies. Am J Obstet Gynecol. 2016;215(4):408–12. doi: 10.1016/j.ajog.2016.06.037 27372270.

9. Knight M, Berg C, Brocklehurst P, Kramer M, Lewis G, Oats J, et al. Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations. BMC Pregnancy Childbirth. 2012;12:7. doi: 10.1186/1471-2393-12-7 22325370.

10. Knight M, Inoss. The International Network of Obstetric Survey Systems (INOSS): benefits of multi-country studies of severe and uncommon maternal morbidities. Acta Obstet Gynecol Scand. 2014;93(2):127–31. doi: 10.1111/aogs.12316 24382256.

11. Halliday LE, Peek MJ, Ellwood DA, Homer C, Knight M, McLintock C, et al. The Australasian Maternity Outcomes Surveillance System: an evaluation of stakeholder engagement, usefulness, simplicity, acceptability, data quality and stability. Aust N Z J Obstet Gynaecol. 2013;53(2):152–7. Epub 2012 Dec 6. doi: 10.1111/ajo.12020 23216366.

12. Deneux-Tharaux C, Bouvier-Colle MH, EPIMOMS study group. Severe acute maternal morbidity in France: the epimoms population-based study. Am J Obstet Gynecol 2017;216(1):S345–S6.

13. Knight M, Kurinczuk JJ, Tuffnell D, Brocklehurst P. The UK Obstetric Surveillance System for rare disorders of pregnancy. BJOG. 2005;112(3):263–5. doi: 10.1111/j.1471-0528.2005.00609.x 15713136.

14. McDonnell N, Knight M, Peek MJ, Ellwood D, Homer CS, McLintock C, et al. Amniotic fluid embolism: an Australian-New Zealand population-based study. BMC Pregnancy Childbirth. 2015;15:352. doi: 10.1186/s12884-015-0792-9 26703453.

15. Krištúfková A, Korbeľ M, Borovský M, Daniš J, Dugátová M. Analysis of severe acute maternal morbidity in Slovak Republic in year 2012. Gynekol. 2015;13(4):185–91.

16. Krištúfková A, Korbeľ M, Daniš J, Dugátová M, Némethová B, Borovský M. Analysis of severe acute maternal morbidity in Slovak Republic in year 2013. Gynekol. 2016;14(2):92–8.

17. Krištúfková A, Korbeľ M, Daniš J, Dugátová M, Némethová B, Borovský M. Analysis of severe acute maternal morbidity in Slovak Republic in year 2014. Gynekol. 2017;15(1):25–32.

18. Farquhar CM, Li Z, Lensen S, McLintock C, Pollock W, Peek MJ, et al. Incidence, risk factors and perinatal outcomes for placenta accreta in Australia and New Zealand: a case-control study. BMJ Open. 2017;7(10):e017713. doi: 10.1136/bmjopen-2017-017713 28982832.

19. Knight M, Ukoss. Antenatal pulmonary embolism: risk factors, management and outcomes. BJOG. 2008;115(4):453–61. doi: 10.1111/j.1471-0528.2007.01622.x 18201281.

20. Knight M, Ukoss. Eclampsia in the United Kingdom 2005. BJOG. 2007;114(9):1072–8. doi: 10.1111/j.1471-0528.2007.01423.x 17617191.

21. Knight M, Kurinczuk JJ, Spark P, Brocklehurst P, United Kingdom Obstetric Surveillance System Steering C. Cesarean delivery and peripartum hysterectomy. Obstet Gynecol. 2008;111(1):97–105. doi: 10.1097/01.AOG.0000296658.83240.6d 18165397.

22. Knight M, Kurinczuk JJ, Spark P, Brocklehurst P, System UKOS. Extreme obesity in pregnancy in the United Kingdom. Obstet Gynecol. 2010;115(5):989–97. doi: 10.1097/AOG.0b013e3181da8f09 20410773.

23. Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. Incidence and risk factors for placenta accreta/increta/percreta in the UK: a national case-control study. PLoS ONE. 2012;7(12):e52893. doi: 10.1371/journal.pone.0052893 23300807.

24. Scott CA, Bewley S, Rudd A, Spark P, Kurinczuk JJ, Brocklehurst P, et al. Incidence, risk factors, management, and outcomes of stroke in pregnancy. Obstet Gynecol. 2012;120(2 Pt 1):318–24. doi: 10.1097/AOG.0b013e31825f287c 22825091.

25. Acosta CD, Kurinczuk JJ, Lucas DN, Tuffnell DJ, Sellers S, Knight M, et al. Severe maternal sepsis in the UK, 2011–2012: a national case-control study. PLoS Med. 2014;11(7):e1001672. doi: 10.1371/journal.pmed.1001672 25003759.

26. Fitzpatrick KE, Hinshaw K, Kurinczuk JJ, Knight M. Risk factors, management, and outcomes of hemolysis, elevated liver enzymes, and low platelets syndrome and elevated liver enzymes, low platelets syndrome. Obstet Gynecol. 2014;123(3):618–27. doi: 10.1097/AOG.0000000000000140 24499757.

27. Fitzpatrick KE, Tuffnell D, Kurinczuk JJ, Knight M. Pregnancy at very advanced maternal age: a UK population-based cohort study. BJOG. 2017;124(7):1097–106. Epub 2016 Sep 1. doi: 10.1111/1471-0528.14269 27581343.

28. Office for National Statistics. Births in England and Wales by Characteristics of Birth2: 2009. Fareham: Office for National Statistics; 2010.

29. Office for National Statistics. Births in England and Wales by Characteristics of Birth2: 2013. Fareham: Office for National Statistics; 2014.

30. Li Z, Zeki R, Hilder L, Sullivan EA. Australia’s mothers and babies 2011. Perinatal statistics series no. 28. PER 59. Canberra: AIHW National Perinatal Epidemiology and Statistics Unit; 2013.

31. Vaughan G, Pollock W, Peek MJ, Knight M, Ellwood D, Homer CS, et al. Ethical issues: the multi-centre low-risk ethics/governance review process and AMOSS. Aust N Z J Obstet Gynaecol. 2012;52(2):195–203. Epub 2011 Dec 20. doi: 10.1111/j.1479-828X.2011.01390.x 22188386.

32. Lucas DN, Yentis SM, Kinsella SM, Holdcroft A, May AE, Wee M, et al. Urgency of caesarean section: a new classification. J R Soc Med. 2000;93(7):346–50. doi: 10.1177/014107680009300703 10928020.

33. The Royal Australian and New Zealand College of Obstetricians. Categorisation of urgency for caesarean section [Internet]. 2015 [cited 2019 Jan 14]. https://ranzcog.edu.au/RANZCOG_SITE/media/RANZCOG-MEDIA/Women%27s%20Health/Statement%20and%20guidelines/Clinical-Obstetrics/Categorisation-of-urgency-for-caesarean-section-(C-Obs-14).pdf?ext=.pdf.

34. Stafford IA, Moaddab A, Dildy GA, Klassen M, Belfort MA, Romero R, et al. Evaluation of proposed criteria for research reporting of amniotic fluid embolism. Am J Obstet Gynecol. 2019;220(3):285–287. Epub 2018 Nov 24. doi: 10.1016/j.ajog.2018.11.1099 30481492.

35. Kramer MS, Abenhaim H, Dahhou M, Rouleau J, Berg C. Incidence, risk factors, and consequences of amniotic fluid embolism. Paediatr Perinat Epidemiol. 2013;27(5):436–41. doi: 10.1111/ppe.12066 23930779.

36. Abenhaim HA, Azoulay L, Kramer MS, Leduc L. Incidence and risk factors of amniotic fluid embolisms: a population-based study on 3 million births in the United States. Am J Obstet Gynecol. 2008;199(1):49 e1–8. doi: 10.1016/j.ajog.2007.11.061 18295171.

37. Leighton BL, Wall MH, Lockhart EM, Phillips LE, Zatta AJ. Use of recombinant factor VIIa in patients with amniotic fluid embolism: a systematic review of case reports. Anesthesiology. 2011;115(6):1201–8. doi: 10.1097/ALN.0b013e31821bdcfd 21720243.

38. Indraccolo U, Battistoni C, Mastrantonio I, Di Iorio R, Greco P, Indraccolo SR. Risk factors for fatality in amniotic fluid embolism: a systematic review and analysis of a data pool. J Matern Fetal Neonatal Med. 2018;31(5):661–5. Epub 2017 Mar 1. doi: 10.1080/14767058.2017.1293034 28282766.

39. Tanaka H, Katsuragi S, Osato K, Hasegawa J, Nakata M, Murakoshi T, et al. Efficacy of transfusion with fresh-frozen plasma:red blood cell concentrate ratio of 1 or more for amniotic fluid embolism with coagulopathy: a case-control study. Transfusion. 2016;56(12):3042–6. doi: 10.1111/trf.13856 27805263.

40. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105–16. doi: 10.1016/S0140-6736(17)30638-4 28456509.

41. MacLennan S, Williamson LM. Risks of fresh frozen plasma and platelets. J Trauma. 2006;60(6 Suppl):S46–50. 16763481.

42. Nascimento B, Goodnough LT, Levy JH. Cryoprecipitate therapy. Br J Anaesth. 2014;113(6):922–34. doi: 10.1093/bja/aeu158 24972790.